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Chicken xenobiotic receptor, pregnane X receptor,
and constitutive androstane receptor are orphan
nuclear receptors that have recently been discov-
ered to regulate drug- and steroid-mediated induc-
tion of hepatic cytochromes P450 (CYP). This in-
duction is part of an adaptive response involving
numerous genes to exposure to drugs and chem-
icals and has major clinical and toxicological im-
plications. Here we report experiments in the
chicken hepatoma cell line LMH that suggest evo-
lutionary conservation of the signaling pathways
triggered by pregnane X receptor, constitutive an-
drostane receptor, and chicken xenobiotic recep-
tor. Thus, the phenobarbital-inducible enhancer
units of the mouse Cyp2b10, rat CYP2B2, and hu-
man CYP2B6 genes were activated in reporter
gene assays by the same compounds that activate
the chicken CYP2H1 phenobarbital-inducible en-
hancer units. Chicken xenobiotic receptor, preg-
nane X receptor, and constitutive androstane
receptor all bound to the CYP2H1 phenobarbital-
inducible enhancer units in gel-shift experiments.
In CV-1 cell transactivation assays, mammalian
pregnane X receptors activate the chicken pheno-
barbital-inducible enhancer units to the same ex-
tent as does chicken xenobiotic receptor, each
receptor maintaining its species-specific ligand
spectrum. To assess the reported role of protein
phosphorylation in drug-mediated induction, we
treated LMH cells with okadaic acid and observed
increased mRNA of -aminolevulinate synthase
and CYP2H1 whereas expression of CYP3A37 was
decreased. The effects of okadaic acid and other
modifiers of protein phosphorylation in LMH cells
are comparable to those seen on CYP2Bs and
CYP3As in mammalian primary hepatocyte cul-
tures. These results indicate that closely related
nuclear receptors, transcription factors, and sig-
naling pathways are mediating the transcriptional
activation of multiple genes by xenobiotics in
chicken, rodents, and man. (Molecular Endocrinol-
ogy 15: 1571–1585, 2001)
A GENE SUPERFAMILY of heme proteins, the cy-tochromes P-450 (CYP), encodes for the main
enzymatic system for metabolism of lipophilic com-
pounds of diverse structures (1). A common feature of
most of these CYP substrates, which include drugs,
fatty acids, cholesterol precursors, and metabolites
such as steroid hormones or bile acids, is their hydro-
phobicity, which enables direct diffusion into cells and
binding to CYPs as well as intracellular receptors (2–
8). A subset of these CYPs can be induced or inhibited
in the liver by a variety of substances, including their
own substrates. Foreign compounds inducing CYPs
can be categorized into different classes represented
by the prototypical substrates dioxin, phenobarbital
(PB), dexamethasone, clofibrate, and ethanol. For ex-
ample, PB and PB-like inducers affect predominantly
the CYP2B, CYP2C, and CYP3A subfamilies (2, 5–9).
Apart from these CYPs, at least 50 other genes are
influenced, triggering a pleiotropic hepatic reaction
characterized by an increase in liver weight, prolifera-
tion of smooth endoplasmic reticulum, and tumor pro-
motion as well as many other effects (10). PB induction
of CYP has been described in a variety of species from
Bacillus megaterium to man. Nevertheless, marked
differences in induction or inhibition potentials of dif-
ferent drugs have been observed in different species.
For instance, whereas the antiglucocorticoid 5-preg-
nen-3-ol-20-one-16-carbonitrile (PCN) is a strong
inducer of CYP3As in rat and mouse, it barely changes
CYP3A levels in man or rabbit (7, 11, 12). In contrast,
5-pregnane-3,20-dione and RU486 (mifepristone)
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are potent CYP3A inducers in man and mouse but
induce to a lesser extent in rabbit or rat (7, 11, 12).
Although the inducing effect of PB and other drugs
was discovered more than 40 yr ago, progress in
understanding the molecular mechanisms of induction
was limited until recently, when transfectable primary
hepatocyte cultures of mice, rat, and chicken were
developed. Reporter gene assays in these in vitro sys-
tems allowed the characterization of drug-responsive
elements in the flanking regions of several inducible
genes and transactivation assays in conjunction with
EMSAs identified transcription factors that bind to
these elements (13–22). However, primary cultures of
hepatocytes have significant drawbacks that hinder
the elucidation of molecular details linking the drug-
induced signal to the transcription machinery. For in-
stance, in primary hepatocyte cultures, the response
to PB is often delayed, attenuated, and terminated
rapidly. In addition, cultured hepatocytes may express
an abnormal CYP profile. Primary hepatocytes are
difficult to transfect, and the time needed for transfec-
tion and drug treatment is excessively long. Moreover,
hepatoma-derived cell lines such as HepG2 do not
express a complete set of CYPs and have lost the
response to PB (for reviews, see Refs. 23 and 24).
In search of a convenient culture system, we dis-
covered the leghorn male hepatoma cell line (LMH) to
respond to PB and PB-like inducers to the same ex-
tent as primary chicken hepatocytes or chick embryo
liver in ovo. The LMH cell line was established by
inducing a hepatocellular carcinoma with diethylnitro-
samine in a male leghorn chicken (25). Characteristi-
cally, the LMH cells feature a well differentiated mor-
phology and biochemistry (25, 26). The biochemical
and chromosomal properties, a triploid karyotype with
six marker chromosomes, remain constant over a pro-
longed period of propagation in culture (25).
Here, we describe the characterization of PB-type
induction in the LMH cells using CYP2H1 and
CYP3A37 as well as -aminolevulinate synthase
(ALAS) as representative genes regulated by PB.
CYP2H1 is one of the major PB-inducible enzymes in
chicken liver (27). CYP3A37, the first avian CYP of the
3A subfamily, was discovered in our laboratory and
shown to be PB inducible (28). ALAS is the first and
rate-limiting enzyme of heme biosynthesis (29). It is
activated to meet the increased need of heme for CYP
heme-proteins (30).
The flanking region of one of these genes, chicken
CYP2H1, has recently been analyzed in detail and a
PB-responsive enhancer unit (PBRU) has been de-
fined (17, 19). Interestingly, the arrangement of certain
putative transcription factor recognition sites, in par-
ticular a nuclear receptor consensus sequence ar-
ranged as a direct repeat of two hexamers separated
by four nucleotides (DR-4) in the vicinity of a nuclear
factor-1 site on the chicken PBRU, is highly conserved
in comparison to PBRUs of mammalian PB-inducible
CYPs (19, 31). This avian 264-bp enhancer element
could be activated by the recently discovered chicken
drug-sensing orphan nuclear receptor, chicken xeno-
biotic receptor (CXR) (22). Sequence comparisons re-
vealed that CXR is closely related to both mammalian
xenobiotic-activated receptors [constitutive andro-
stane receptor (CAR) and pregnane X receptor (PXR)]
showing between 61% and 67% amino acid identity in
the DNA-binding domains and between 49% and 56%
amino acid identity in the ligand-binding domains, re-
spectively (22). We therefore wanted to test whether
these orphan nuclear receptors interact with the avian
PBRU.
Both drug-induction and orphan nuclear receptor
signaling have been reported to be highly influenced
by phosphorylation and dephosphorylation events
(32–35). We studied the effects of the protein phos-
phatase inhibitor okadaic acid and the cAMP modu-
lator forskolin on CYP2H1, CYP3A37, and ALAS as
well as the effects of inducers on cAMP levels in the
LMH cells to determine whether phosphorylation and
dephosphorylation events elicit the same effects in
LMH cells as those previously reported for primary
cultures of rat and mouse hepatocytes (36–40).
The data presented here demonstrate the inter-
changeability of drug-responsive elements and xeno-
biotic-activated nuclear receptors in chicken and
mammals and also suggest conservation of protein
phosphorylation and dephosphorylation effects on in-
duction in these different species.
RESULTS
PB Induction of CYP2H1 in the Chicken
Hepatoma Cell Line LMH
To assess the inducibility of the LMH cell line by xe-
nobiotics, CYP2H1 transcript and protein levels were
measured after drug treatment. Induction of CYP2H1
mRNA was dose dependent with maximal transcript
levels after treatment with 1 mM PB as shown by both
semiquantitative PCR and Northern blot (Fig. 1A).
Higher PB concentrations produced significant cell
toxicity. In Northern blots, a band of about 3.5 kb
corresponding to CYP2H1 was observed (Fig. 1A). As
shown in Fig. 1B, transcript levels of CYP2H1 contin-
ued to rise even after 30 h of exposure to 600 M PB.
PB induction of CYP2H1 was dose dependent and
reversible at the mRNA level. Similar results were ob-
tained with mRNA of -aminolevulinic acid synthase
(data not shown) and CYP3A37 (28). When comparing
protein levels of CYP2H1 in chicken embryo liver (in
ovo) with those of chicken primary hepatocytes and
LMH cells, we observed that control and PB-treated
protein levels in the LMH cells reflected the in ovo
situation better than the chicken primary hepatocytes
(Fig. 1C). LMH cells were exposed to 600 M PB for
24 h, chicken embryo hepatocytes were exposed to
1.2 mM PB for 48 h, and chick embryos were treated
with 3 mg PB per egg for 48 h. Basal levels in ovo and
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in the LMH cells were lower than those in chicken
embryo hepatocytes, but consistent induction could
be seen in all three systems. The identities of the upper
bands in the Western blot are not yet clear. We have
found members of the CYP2C subfamily in chicken
(data not shown), and these bands might represent
CYP2Cs that are recognized by the polyclonal CYP2H1
antibody due to the close relationship of CYP2Cs and
CYP2Hs. Nevertheless, these bands are clearly distin-
guishable from the band representing CYP2H1 by
their higher molecular weight. Induction of CYP3A37
protein by PB in the LMH cells has previously been
demonstrated (28).
A 4.8-kb fragment of the 5-flanking region of
CYP2H1, which has been shown to be a PB-respon-
sive enhancer element (41), was cloned into a
pBLCAT5-reporter vector containing an enhancerless
thymidine kinase (tk)-promoter and transfected into
LMH cells. Nonradioactive chloramphenicol acetyl-
transferase (CAT) reporter gene assays were per-
formed, and a dose-dependent increase in CAT pro-
tein was observed amounting to a 60-fold induction at
200 M PB after 48 h (Fig. 1D). This response is higher
than the induction levels obtained in chicken primary
hepatocytes after a 48 h exposure to 400 M PB,
resulting in a 20-fold increase (data not shown). In
experiments reported by another laboratory (17, 41),
the 4.8-kb enhancer fragment cloned into a pCAT-
reporter vector containing the weak, enhancerless
SV40 promoter gave a 7- to 14-fold induction after
treatment of chicken primary hepatocytes with 500 M
PB for 48 h. Thus, LMH cells provide a reliable tool that
is as highly drug-responsive as are in ovo systems
(Fig. 1C).
Fig. 1. Inducibility of LMH Cells
A, LMH cells were exposed to different concentrations of PB for 24 h. RNA was isolated and reverse-transcribed, and the level
of CYP2H1 and -actin cDNA was measured by semiquantitative PCR and Northern blot. CYP2H1 levels were adjusted relative
to -actin levels. Data represent the average of three independent experiments with error bars representing standard deviations.
B, LMH cells were treated with 600 M PB for the indicated time period, and transcript levels of CYP2H1 and -actin were
measured. Data represent the average of three independent experiments with error bars representing standard deviations. C,
LMH cells were exposed to 600 M PB for 24 h, chicken embryo hepatocytes (CEH) were exposed to 1.2 mM PB for 48 h, and
chicken embryos in ovo were treated with 3 mg PB per egg for 48 h before preparation of liver homogenate. Protein from chicken
liver homogenate, primary cultures of chicken hepatocytes, and LMH cells was isolated and a Western blot performed with
CYP2H1 antibodies as described in Materials and Methods. D, LMH cells were transfected with the 4.8-kb PB-responsive
enhancer from CYP2H1 in pBLCAT5 containing an enhancerless tk-promoter. After exposure to the indicated concentrations of
PB for 48 h, a CAT ELISA was performed. The relative CAT expression was standardized against untreated control cells and
expressed as fold induction. Data represent the average of three independent experiments with error bars representing standard
deviations.
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Mammalian Drug-Responsive Enhancer Elements
Are Activated in the Chicken LMH Cells
In previous experiments, we have observed that a
51-bp PBREM from the mouse Cyp2b10 5-flanking
region (15) was activated by PB-like inducers in the
LMH cell line (19). To extend these studies, we tested
the response elements of the rat CYP2B2 (13, 16), the
human CYP2B6 (18), and the mouse Cyp2b10 (15)
gene with different inducers in LMH cells and com-
pared the results to the findings of the chicken 264-bp
PBRU (19). The 163-bp PBRU of rat CYP2B2, the
51-bp PBREM of human CYP2B6, the 51-bp PBREM
of mouse Cyp2b10, and the 264-bp PBRU of chicken
CYP2H1 subcloned in reporter gene vectors were
transfected into LMH cells, and reporter gene assays
were performed after applying different inducers for
16 h (Fig. 2). We selected the same drugs as those
used in previous studies of the chicken 264-bp PBRU
and the mouse Cyp2b10 PBREM (19). As prototypical
CYP2B gene activators, we used PB (400 M) and the
PB-like inducers propylisopropylacetamide (PIA) (250
M) and glutethimide (500 M). The two CYP3A induc-
ers dexamethasone (50 M) and metyrapone (400 M)
were also examined. Rifampicin (100 M) and PCN (50
M) have species-specific effects on CYP3As and
were therefore of interest. Furthermore, LMH cells
were treated with the prototypical CYP1A1-inducer
-naphtoflavone (10 M). In general, both the human
and the rat response element reacted in the same way
to the different inducers varying only in the extent of
the inductions (Fig. 2, A and B). PB-induction of the rat
163-bp PBRU was 6-fold in contrast to the human
51-bp PBREM that was 1.5-fold induced. High induc-
tion on both elements was observed when using PIA,
glutethimide, or metyrapone. PIA conferred a 68-fold
induction on the rat PBRU and a 6.1-fold induction on
the human PBREM, slightly higher than the 34-fold
induction of the rat PBRU and the 4.2-fold induction of
the human PBREM by glutethimide. Metyrapone in-
duced the rat PBRU 46-fold and the human PBREM
8.1-fold. Dexamethasone, PCN, rifampicin, and
-naphtoflavone had no or only very minor effects on
both elements (Fig. 2, A and B). These results demon-
strate that the rat 163-bp PBRU and the human 51-bp
PBREM react comparably to the chemicals. Moreover,
these inductions correspond to the reporter gene ac-
tivations by the chicken 264-bp PBRU and the mouse
51-bp PBREM in LMH cells (Fig. 2, C and D). The differ-
ent relative magnitude of the responses to different
drugs might be explained by recent findings demonstrat-
ing that the 163-bp PBRUs and the 51-bp PBREMs are
not equivalent in their response to different inducers and
that additional transcription factor-binding sites on the
163-bp PBRU contribute to maximal induction (42). The
mouse and the chicken enhancer reacted almost iden-
tically to drug treatment as observed previously (19).
Consequently, the same or very similar receptors in the
chicken LMH cells can bind to and activate the different
response elements from human, rat, mouse, and chicken
after drug treatment.
Human PXR and Human CAR Bind to the
Chicken CYP2H1 264-bp PBRU in Gel-EMSAs
Since the drug-response elements are exchangeable
between chicken, mouse, rat, and human, we wanted
to test whether the different xenobiotic-sensing nu-
clear receptors PXR, CAR, and CXR from human and
chicken bind to the CYP2H1 264-bp PBRU. None of
the in vitro transcribed/translated receptors bound to
radiolabeled 264-bp PBRU as monomers (Fig. 3, lanes
2–5). Heterodimerized with chicken RXR, both human
PXR and human CAR formed a complex on the CYP2H1
PBRU as did the CXR/RXR complex (Fig. 3, lanes 6, 8,
and 10, region b). These complexes could be super-
shifted when using an antibody against RXR (Fig. 3, lanes
7, 9, and 11, region c). Thus, all three drug-activated
nuclear receptors, PXR, CAR, and CXR, could be shown
to interact with the chicken PBRU.
Human and Mouse PXR Transactivate the
Chicken 264-bp PBRU in CV-1 Cells
As mammalian xenobiotic-sensing orphan nuclear re-
ceptors are binding to the chicken 264-bp PBRU,
functional tests were performed to determine whether
these receptors also activate the avian response ele-
ment. In contrast to CXR and PXR, CAR activation by
PB is not measurable in CV-1 cell transactivation as-
says for the following reasons: 1) CAR is a constitu-
tively active transcription factor (43, 44); 2) PB appar-
ently is not a ligand of CAR but induces by an indirect
mechanism involving cytoplasmic-nuclear transfer of
CAR (35, 45); 3) transiently or stably expressed CAR is
exclusively nuclear in cultured cells (35, 45). Due to
these limitations, we restricted the transactivation ex-
periments to PXR and CXR in this study. Monkey
kidney epithelial CV-1 cells were cotransfected with
the reporter gene construct containing the 264-bp
PBRU and the expression plasmid for CXR, human
PXR, and mouse PXR, respectively. Cells were treated
for 24 h with different inducer compounds and reporter
gene levels were measured. Mammalian PXRs and
chicken CXR all were able to transactivate the chicken
264-bp PBRU. Moreover, activation patterns corre-
sponded to the relative potencies of induction ob-
served with a CYP3A4-responsive enhancer module
and recapitulated the typical species-specific differ-
ences between human and mouse PXR (46). Thus, in
CV-1 cells, human PXR was strongly activated by PB,
glutethimide, metyrapone, RU486, rifampicin, and clo-
trimazole whereas dexamethasone, RU486, and PCN
activated mouse PXR (Fig. 4, A and B). The CYP2H1
264-bp PBRU is also activated by the chicken drug-
activated orphan nuclear receptor CXR that was re-
cently discovered in this laboratory (22). When com-
paring the activation patterns of mouse PXR, human
PXR, and chicken CXR, CXR had almost identical
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specificity for ligands as human PXR concerning PB,
dexamethasone, metyrapone, PCN, clotrimazole, and
TCPOBOP (Fig. 4, A and C). Overlap between CXR
and mouse PXR activation patterns was also observed
after treatment with glutethimide and rifampicin (Fig. 4,
B and C). In contrast, CXR was the only receptor that
was activated by -naphtoflavone and by PIA and the
only receptor not affected by RU486 (Fig. 4C). These
data indicate overlapping ligand specificity for these
evolutionary distant receptors. Moreover, all three re-
ceptors could bind to the chicken enhancer element
and transactivate this PBRU upon drug treatment us-
ing the transcriptional machinery of the monkey epi-
thelial kidney cells.
Fig. 2. Trans-species Activation of Rat CYP2B2 163-bp PBRU, Human CYP2B6 51-bp PBREM, Mouse Cyp2b10 51-bp PBREM,
and Chicken CYP2H1 264-bp PBRU in LMH Cells
The PB-responsive elements from human CYP2B6 (A), rat CYP2B2 (B), mouse Cyp2b10 (C), and chicken CYP2H1 (D) genes
were cloned into the pBLCAT5 reporter vector containing a tk promoter as described in Materials and Methods and Ref. 19. These
constructs were transfected into LMH cells in suspension, and the cells were induced for 16 h with PB (400 M), PIA (250 M),
glutethimide (500 M), dexamethasone (50 M), metyrapone (400 M), PCN (50 M) rifampicin (100 M), or -naphtoflavone (10
M). Cells were harvested and a CAT-ELISA was performed. The relative CAT expression was standardized against untreated
control cells and expressed in fold induction. Values represent the average of three independent experiments with error bars
representing standard deviations.
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The DR-4 Element Within the CYP2H1 264-bp
PBRU is the Main Binding and Activation Site for
PXR, CAR, and CXR
Nuclear receptor binding sites consisting of two direct
repeats of nucleotide hexamers with the consensus
sequence AGT/GTCA separated by four nucleotides
(DR-4) have been identified to constitute the binding
sites for xenobiotic-sensing orphan nuclear receptors
on mammalian and chicken PBRUs and to confer drug
inducibility of those (15, 16, 18, 19, 21). To assess the
importance of this DR-4 in cross-species experiments,
we compared the effects of the CYP2H1 264-bp
PBRU containing mutated hexamer half-sites in its
DR-4 (called “double,” described in Ref. 19) to those of
wild-type CYP2H1 264-bp PBRU (wt). EMSAs re-
vealed that the mutated CYP2H1 264-bp PBRU was
no longer able to bind either CXR, human PXR, or
human CAR heterodimerized to chicken RXR (Fig.
5A, lanes 4, 6, and 8) in contrast to the wild-type
264-bp PBRU (Fig. 5A, lanes 3, 5, and 7). Moreover,
the mutated 264-bp PBRU was also compared with its
wild-type counterpart in CV-1 cell transactivation as-
says with human PXR, mouse PXR, and CXR. After
transfection, CV-1 cells were treated with either vehi-
cle [0.1% dimethylsulfoxide (DMSO)], RU486 (10 M),
PCN (50 M), or clotrimazole (10 M) for 24 h. Cell
extracts were analyzed for CAT expression normalized
against -galactosidase levels. These compounds
were chosen because of their ability to strongly induce
either human PXR (RU486, clotrimazole), mouse PXR
(RU486, PCN), or CXR (clotrimazole) as shown in Fig.
4. Activation levels of all three receptors were severely
reduced on the 264-bp PBRU DR-4 double mutant
compared with the wild-type PBRU (Fig. 5, B, C, and
D). The species-specific induction levels of human
PXR by RU486 and clotrimazole, mouse PXR by
RU486 and PCN, and CXR by clotrimazole were
strongly reduced on the 264-bp CYP2H1 PBRU DR-4
Fig. 3. Human PXR and Human CAR Bind to the Chicken 264-bp PBRU in EMSAs
Radiolabeled 264-bp PBRU was incubated with in vitro transcribed/translated CXR (lanes 3, 6, and 7), human PXR (lanes 4,
8, and 9), human CAR (lanes 5, 10, and 11), chicken RXR (lanes 2 and 6–11), and anti-RXR antibody (lanes 7, 9, and 11). The
arrow depicts unbound probe (a). Complexes of CXR, human PXR, and human CAR with chicken RXR result in shifts (b) and with
addition of anti-RXR antibody in supershifts (c).
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double mutant in comparison with the wild-type
264-bp PBRU. Both the EMSA and the transactivation
experiments thus underline the importance of the
DR-4 element within the CYP2H1 264-bp PBRU in
drug induction.
Okadaic Acid Affects Drug-Induction of CYP2H1,
CYP3A37, and ALAS
In diverse in vitro systems including rat and mouse
primary hepatocyte cultures, both nuclear receptor
activity and drug induction of CYPs have been shown
to be modulated by diverse protein kinases and pro-
tein phosphatases (for reviews, see Refs. 32 and 34).
Okadaic acid (OA) is an inhibitor of various protein
phosphatases (PP) of which PP-1, PP-2A, and PP-2B
are the best studied among those thought to be af-
fected (47). We used OA as a tool to inhibit PPs and
measure their effect on induction of ALAS, CYP2H1,
and CYP3A37 by semiquantitative RT-PCR using the
Taqman system. In preliminary dose-response exper-
iments, OA induced CYP2H1 and ALAS mRNA levels
at concentrations of about 100 nM whereas CYP3A37
mRNA levels were inhibited by 10 nM OA (data not
shown). We therefore used 1 M OA in the following
coincubation experiments to obtain clear results for all
three genes. To get a general overview of induction
pathways affected by PP, we tested the effect of OA
treatment on inducers of three different types, namely
PB, dexamethasone, a synthetic glucocorticoid, and
metyrapone, a substituted pyridine. LMH cells were
induced with 400 M PB, 50 M dexamethasone, and
400 M metyrapone alone and together with 1 M OA
or 1 M 1-nor-okadaone, an inactive analog of OA.
After 16 h, transcript levels of ALAS, CYP2H1, and
CYP3A37 were determined (Fig. 6). PB, dexametha-
sone, and metyrapone induced ALAS, CYP2H1, and
CYP3A37 with metyrapone being the strongest in-
ducer, most impressive in the case of CYP3A37 (Fig.
6C). In contrast to 1-nor-okadaone, OA had profound
effects on all three enzymes, i.e. increase of ALAS and
CYP2H1 transcript level in contrast to complete inhi-
bition of CYP3A37 induction by PB, dexamethasone,
or metyrapone (Fig. 6). When OA was added in com-
bination with PB, dexamethasone, or metyrapone,
there was no increase in transcript levels of ALAS and
CYP2H1 over the levels achieved with OA alone, sug-
gesting that OA affects the mechanism by which drugs
activate transcription (Fig. 6). This effect is best seen in
coexposures to OA and metyrapone for ALAS, where
transcript levels were even lowered by combined
treatment compared with metyrapone alone. The ef-
fects of OA were confirmed at the protein level by
Western blotting for CYP2H1 and CYP3A37 (data not
shown). Thus, the inhibition of PB induction of CYPs,
as observed for rat CYP2B2 and mouse Cyp2b10 in
primary cultures of hepatocytes, could also be shown
for chicken CYP3A37 on mRNA levels in LMH cells.
The apparently paradoxical CYP2H1 mRNA induction
Fig. 4. Human and Mouse PXR and Chicken CXR Activate the Avian 264-bp PBRU in CV-1 Transactivation Assays
CV-1 cells were cotransfected with expression plasmids for either human PXR (A), mouse PXR (B), or chicken CXR (C) together
with a CAT reporter gene plasmid containing the CYP2H1 264-bp PBRU as described in Ref. 22. Cells were then treated with
vehicle (0.1% DMSO), PB (400 M), PIA (250 M), glutethimide (500 M), TCPOBOP (10 M), dexamethasone (50 M), metyrapone
(400 M), RU486 (10 M), PCN (50 M), rifampicin (100 M), -naphtoflavone (10 M), or clotrimazole (10 M) for 24 h. Cell extracts
were analyzed for CAT expression normalized against -galactosidase levels. Values are the average of three independent
experiments and the error bars represent standard deviations.
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Fig. 5. The DR-4 Element Within the CYP2H1 264-bp PBRU Confers Binding and Inducibility by PXR, CAR, and CXR
A, Radiolabeled wild-type 264-bp PBRU (wt, lanes 1, 3, 5, and 7) or 264-bp PBRU mutated in both hexamers of the DR-4
element (double, lanes 2, 4, 6, and 8) were incubated with in vitro transcribed/translated CXR (lanes 3 and 4), human PXR (lanes
5 and 6), and human CAR (lanes 7 and 8) together with chicken RXR (lanes 3–8). The arrow depicts unbound probe (a) and the
complexes of CXR, human PXR, and human CAR with chicken RXR resulting in a shifts (b). B, C, and D, CV-1 cells were
cotransfected with expression plasmids for either human PXR (B), mouse PXR (C) or chicken CXR (D) together with a CAT reporter
gene plasmid containing the wild-type CYP2H1 264-bp PBRU (wt) or the CYP2H1 264-bp PBRU containing mutated hexamer
half-sites in its DR-4 element (double). Cells were then treated with vehicle (0.1% DMSO), RU486 (10 M), PCN (50 M), or
clotrimazole (10 M) for 24 h. Cell extracts were analyzed for CAT expression normalized against -galactosidase levels. Values
are the average of three independent experiments, expressed as percent of maximal induction levels, and the error bars represent
standard deviations.
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can be explained by previous findings showing that PB
induction on the CYP2H1 264-bp PBRU is inhibited by
OA and the observed overall induction of CYP2H1 is
due to activation of its promoter by OA (19).
PB Does Not Change cAMP Levels in LMH Cells
To study drug-mediated changes in second messen-
ger systems involved in phosphorylation and dephos-
phorylation events, we measured the intracellular
cAMP levels in the LMH cells after treatment with PB
and modulators of cellular cAMP levels using a non-
radioactive, competitive immunoassay. In rat and
mouse primary hepatocytes, PB modulated neither
cAMP levels nor PKA activities (39, 40). In LMH cells,
forskolin, an activator of adenylate cyclase, elevated
intracellular cAMP 30 min after addition to the LMH
cells from 0.9 pmol/ml to 1,323 pmol/ml (Fig. 7). Six-
teen hours later, cAMP levels were not higher than in
control cells, comparable to the kinetics described
Fig. 6. OA Affects PB-, Dexamethasone-, and Metyrapone Induction of ALAS, CYP2H1, and CYP3A37
LMH cells were treated with 1 M OA or 1 M 1-nor-okadaone for 16 h in combination with either 400 M PB, 50 M
dexamethasone, or 400 M metyrapone. Total RNA was isolated and reverse transcribed. Relative mRNA levels of ALAS (A),
CYP2H1 (B), and CYP3A37 (C) from treated cells against control cells were determined with a Taqman ABI PRISM 7700 Sequence
Detection System (Applied Biosystems, Rotkreuz, Switzerland) and normalized against GAPDH mRNA level as described in
Materials and Methods. Values are the average of three independent experiments and the error bars represent standard
deviations.
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previously in primary rat and mouse hepatocytes (36,
39, 40). Treatment with PB or 1,9-dideoxyforskolin, a
negative analog of forskolin, had no effect on intracel-
lular cAMP level. As expected, none of these three
compounds could raise cAMP levels in the medium to
a detectable concentration. The cAMP analog
(Bu)2cAMP could be detected in the cells, both after
30 min and after 16 h, at a high concentration of
approximately 9,500 pmol/ml whereas another cAMP
analog, 8-(4-chlorophenylthio)-cAMP (CPT-cAMP),
was less potent (Fig. 7). Both analogs were designed
for easy penetration in cell culture systems, and
(Bu)2cAMP was apparently more stable compared
with CPT-cAMP in LMH cell cultures. These and pre-
vious results demonstrate that PB treatment of
chicken LMH cells and of primary hepatocytes of rat
and mouse has no effect on the second messenger
cAMP.
Forskolin Activates CYP2H1, CYP3A37, and ALAS
Independently of Adenylate Cyclase and cAMP
No effect of forskolin on CYP2b10 was observed in
primary cultures of mouse hepatocytes (39), but fors-
kolin affected rat CYP2B1/2 and rat CYP3A1 tran-
scription in primary hepatocytes in different ways. In
contrast to the inhibition of CYP2B1/2 (48), an induc-
tion of CYP3A1 by forskolin was proposed to be due to
adenylate cyclase-independent effects since the ana-
log 1,9-dideoxyforskolin, which shows no adenylate
cyclase-activation, had the same inducing effect (36).
Transcript levels of CYP2H1, CYP3A37, and ALAS
were determined after treating LMH cells for 16 h with
400 M PB, 100 M forskolin, 100 M 1,9-dideoxyfor-
skolin, or 100 M (Bu)2cAMP. No effect of (Bu)2cAMP
on any of the three enzymes was observed (Fig. 8)
whereas both forskolin and 1,9-dideoxyforskolin ele-
vated mRNA levels of ALAS, CYP2H1, and CYP3A37
(Fig. 8). Thus, the effect of forskolin and 1,9-dideoxy-
forskolin is apparently independent of adenylate cy-
clase activation and cAMP levels in the chicken LMH
cells, similar to regulation of rat CYP3A1 in primary
hepatocyte cultures (36). Whereas CYP2B2 and
CYP3A1 in rat both were inhibited by cAMP (50), our
results correlate with the lack of effect of cAMP on
mouse Cyp2b10 in primary hepatocytes (39) showing
no effect of cAMP on PB-inducible enzymes. Thus,
comparisons of our data with previous results in pri-
mary cultures of rat and mouse hepatocytes show a
high conservation of protein phosphorylation and de-
phosphorylation events in enzyme induction triggered
by drug treatment between chicken and rodents (36,
37, 39, 40).
DISCUSSION
Drug-Responsive Enhancer Units and Xenobiotic-
Sensing Receptors Are Conserved in Chicken,
Rodents, and Man
CYP induction by drugs and xenobiotics has been
observed in a wide range of species (2, 4–9). However,
there are major interspecies differences in the spec-
trum of inducer drugs and the pattern of activated
genes (7, 11, 12). The molecular origin of this diver-
gence has remained unclear. The results summarized
in this report demonstrate conservation of the basic
mechanism of drug induction between different spe-
cies and suggest that divergent ligand-binding do-
mains of orphan nuclear receptors account for the
observed species differences. These conclusions are
deduced from the following observations: First, drug-
responsive elements from the human CYP2B6, the rat
CYP2B2, the mouse Cyp2b10, and the chicken
CYP2H1 could be activated in the chicken LMH cells.
The response elements showed similar activation pat-
terns after treatment with different drugs that closely
resembled the CXR-mediated activation pattern of the
Fig. 7. Effect of Drug Treatment on cAMP Levels in the LMH
Cells
LMH cells were treated with 400 M PB, 100 M forskolin,
100 M 1,9-dideoxyforskolin, 100 M (Bu)2cAMP or 100 M
CPT-cAMP for either 30 min or 16 h. Cells were harvested,
and a competitive immunoassay was used to measure intra-
cellular cAMP and cAMP in the medium. Values are the
average of three independent experiments and the error bars
represent standard deviations. Concentrations below detec-
tion limits are designated n.d. (nondetectable).
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chicken CYP2H1 PBRU in CV-1 cell transactivation
assays as well. These data suggest that mammalian
enhancers also interact with CXR. Similarly, all ele-
ments are highly conserved in their structure of tran-
scription factor binding sites of which a direct repeat
of hexamer half-sites separated by four nucleotides
(DR-4) is responsible for binding of the xenobiotic-
sensing orphan nuclear receptor heterodimers (19).
Second, the three different members of drug-sensing
orphan nuclear receptors CXR, PXR, and CAR bound
the chicken 264-bp PBRU in EMSAs. Moreover, in
CV-1 cell transactivation assays, the mammalian PXRs
could activate the chicken CYP2H1 PBRU to the same
extent as the chicken CXR. Thus, in monkey CV-1
cells, the dynamic multiprotein complex required for
the induction machinery is able to cross-react with the
chicken, human, and mouse receptors and the
chicken response element. We interpret these data as
support for the concept that species differences in
drug induction are due to divergent ligand-binding
domains of the xenobiotic-sensing orphan nuclear re-
ceptors and not to fundamental differences in the in-
duction mechanism. The 60% to 80% amino acid
sequence similarity in the ligand-binding domain of
drug-activated orphan nuclear receptor orthologs is
significantly lower than the 90% amino acid similarity
observed in principle between nuclear receptor or-
thologs. Accordingly, mice devoid of endogenous PXR
that are rescued with human PXR exhibit a humanized
xenobiotic response (49). These findings indicate that
it is exclusively the ligand-binding domain of drug-
sensing orphan nuclear receptors that independently
Fig. 8. Influence of Forskolin and cAMP on ALAS, CYP2H1, and CYP3A37
LMH cells were treated with 100 M forskolin, 100 M 1,9-dideoxyforskolin, or 100 M (Bu)2cAMP for 16 h with or without 400
M PB. Total RNA was isolated and reverse transcribed. Relative mRNA levels of ALAS (A), CYP2H1 (B), and CYP3A37 (C) from
treated cells against control cells were determined with a Taqman ABI PRISM 7700 Sequence Detection System and normalized
against GAPDH mRNA level as described in Materials and Methods. Values are the average of three independent experiments
and the error bars represent standard deviations.
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diverged during evolution of species as a reaction to
different environmental challenges (7, 12, 49).
Drug-Induction Mechanisms in Birds and
Mammals Are Similarly Affected by Protein
Phosphorylation and Dephosphorylation Events
The conservation of xenobiotic-triggered signaling
pathways and the protein-protein interactions involved
therein are further supported by our observations on
the effect of modifiers of protein phosphorylation on
drug induction. Although only CYP3A37 mRNA levels
were reduced by OA, we showed previously that in-
duction of CYP2H1 by OA is predominantly mediated
by a 205-bp core promoter fragment whereas drug
induction of the 264-bp PBRU is abolished by OA (19).
Thus, the inhibition of CYP induction by OA correlates
with the CYP inhibitions in rat and mouse. Moreover,
nuclear translocation of the drug-sensing orphan nu-
clear receptor CAR triggered by drug treatment could
be inhibited by OA leading to repression of CYP in-
duction in mouse liver (35). These results suggest that
PPs play an important role in the molecular mecha-
nism of CYP induction. In contrast, cAMP levels were
not affected by drug treatment, and the CYP induction
triggered by the adenylate-cyclase activator forskolin
apparently is not linked to changes in cAMP in the cell.
Forskolin mediates a multitude of physiological effects
that cannot be reproduced by cAMP analogs, i.e. in-
hibiting a variety of membrane proteins such as mem-
brane transporters, voltage-sensitive channels, or P-
glycoprotein. The diterpenic structure of forskolin is
related to steroids, and forskolin might therefore ex-
hibit steroid-like properties (see Ref. 36 and references
therein). More recently, forskolin was found to activate
the farnesoid X receptor (FXR), the bile acid receptor in
liver, kidney, and intestine that is involved in regulation
of CYP7A, a key enzyme in cholesterol homeostasis
(50–52). Overlapping ligand affinities to different or-
phan nuclear receptor also have been observed for
troglitazone, a drug used for treatment of type 2 dia-
betes that activates both the PPAR and PXR. Similarly,
SR12813, a compound that lowers cholesterol levels
in a number of species, activates both FXR and PXR
(12). These findings indicate that most, if not all, xe-
nobiotic inducer compounds affect more than one
nuclear receptor system and that pronounced cross-
talk exists between receptors that bind lipophilic
drugs, fatty acids, steroids, and cholesterol derivatives
such as CXR, PXR, CAR, FXR, and PPAR. In summary,
these results in LMH cells demonstrate that both the
orphan nuclear receptors and the signaling mecha-
nisms affecting drug-induction pathways are similar in
different species in spite of previous findings that pro-
posed different proteins and transcription factors to be
responsible for CYP induction in chicken compared
with mammals (17).
The studies reported in this manuscript were possi-
ble by using a new, drug-inducible experimental sys-
tem, the chicken hepatoma cell line LMH. The LMH
cells offer the advantages of a continuously dividing
culture system, including the availability of frozen
stocks of clonal origin, long-term culture, high com-
parability, and transfection efficiency. LMH cells there-
fore allow the development of new experimental tools
to study the molecular details of the effects of xeno-
biotics on gene expression, such as subclones with
permanently expressed or mutated transcription fac-
tors or induction-resistant cell mutants suitable for
complementation experiments.
MATERIALS AND METHODS
Reagents
OA sodium salt, 1-nor-okadaone, forskolin, and 1,9-dide-
oxyforskolin were purchased from Alexis Biochemicals
(La¨ufelfingen, Switzerland). Dexamethasone, metyrapone
(2-methyl-1,2-di-3-pyridyl-1-propanone), PCN, rifampicin,
clotrimazole (1-[o-chlorotrityl]-imidazole), CPT-cAMP, and
(Bu)2cAMP) were obtained from Sigma (Buchs, Switzerland).
PIA was generously provided by Dr. P. Sinclair (VA Hospital,
White River Junction, VT). Glutethimide and -naphtoflavone
were purchased from Aldrich (Buchs, Switzerland). RU486
was obtained from Roussel-UCLAF SA (Paris, France).
TCPOBOP (1, 4-bis[2-(3, 5-dichloropyridyloxy)]benzene) was
a gift from Dr. U. Schmidt (Institute of Toxicology, BAYER AG,
Wuppertal, Germany). PB sodium salt (5-ethyl-5-phenyl-
barbituric acid sodium salt) was purchased from Fluka Chem-
ical Co. (Buchs, Switzerland). All other reagents were from
standard suppliers. Cell culture media, sera, and tissue cul-
ture reagents were purchased from Life Technologies, Inc.
(Basel, Switzerland) unless noted otherwise.
Plasmids
The rat CYP2B2 163-bp PBRU was amplified from rat
genomic DNA, and the PCR product was digested with
Sau3AI and subcloned into a BamHI-digested pBlueScript
vector. From a clone containing two copies in head-to-tail
orientation, the insert was excised with XbaI and HindIII and
ligated into the pBLCAT5 reporter gene vector. The coding
regions of human and mouse CAR were amplified from hu-
man and mouse cDNA, respectively, followed by subcloning
into the expression vector pSG5 (Stratagene, Basel, Switzer-
land). The expression vectors for human and mouse PXR,
pSG5-hPXR, and pSG5-mPXR.1, kindly provided by Dr. S. A.
Kliewer (Department of Molecular Endocrinology, Glaxo Well-
come Inc. Research and Development, Research Triangle
Park, NC), were described in previous publications (11, 20).
The reporter gene vector containing the human CYP2B6
51-bp PB-responsive enhancer module (PBREM), a kind gift
of Dr. M. Negishi (NIEHS, NIH, Research Triangle Park, NC),
was described previously (18).
Culture and Transfection of LMH Cells
LMH cells were obtained from the American Type Culture
Collection (Manassas, VA) and thawed immediately after ar-
rival. Cultivation in William’s E medium and transfection with
FuGENE 6 Transfection Reagent (Roche Molecular Bio-
chemicals, Rotkreuz, Switzerland) were performed as de-
scribed previously (22).
cAMP Determination
The levels of cAMP were determined by using the Format A
Cyclic AMP Enzyme Immunoassay Kit (BIOMOL Research
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Laboratories, Inc., Plymouth Meeting, PA) according to the
instructions of the manufacturer. Briefly, cells were incubated
with the drugs for 30 min or 16 h and lysed. Intracellular
cAMP and cAMP levels in the medium were measured using
a competitive immunoassay.
Analysis of Reporter Gene Expression
Sixteen hours after drug treatment, the cells were harvested
and nonradioactive chloramphenicol acetyltransferase (CAT)
assays were performed using the CAT-ELISA kit according to
the manual of the supplier (Roche Molecular Biochemicals).
Cell extracts were also used for the determination of protein
concentration using the ESL protein assay for normalization
of specific CAT expression to total protein content (Roche
Molecular Biochemicals).
RNA Isolation and SQRT-PCR Analysis
RNA purification and cDNA synthesis were performed as
described previously (30). The primers for each cDNA ampli-
fication were designed to be specific and selective for the
predicted sequences. For chicken CYP2H1, the primers used
for RT-PCR analysis were the following: forward 5-GAC ACT
TGA CAT CTC TTC CTC-3, and reverse 5-CTG GGC ATT
GAC TAT CAT T-3, and amplified a 1,572-bp fragment. In
parallel, we analyzed chicken -actin as an internal control for
normalization. The forward and reverse primers, 5-CCC TGA
ACC CCA AAG CCA AC-3 and 5-GAC TCC ATA CCC AAG
AAA GA-3, respectively, produced a predicted 487-bp frag-
ment between positions 394 and 880. The conditions for
cDNA amplification have been described previously (30).
RNA Isolation and Taqman Analysis
RNA from LMH cells was isolated with the RNeasy Kit (QIA-
GEN AG, Basel, Switzerland). One microgram of total RNA
was reverse-transcribed with the Moloney murine leukemia
virus reverse transcriptase (Roche Molecular Biochemicals).
PCR was performed using the Taqman PCR Core Reagent
Kit (PE Applied Biosystems, Rotkreuz, Switzerland) and the
transcript level quantitated with an ABI PRISM 7700 Se-
quence Detection System (PE Applied Biosystems, Rotkreuz,
Switzerland) according to the manufacturers protocol. Briefly,
relative transcript levels in induced cells and nontreated con-
trol cells were determined using the relative quantitation
method measuring the Ct. The following primers and flu-
orescent probes were used in these PCR reactions: CYP2H1:
probe, 5-TCG CAG TTG CCT CCA GGT CTC CC-3; forward
primer, 5-AGG GTG GTG AGG GCA AAT C-3; reverse
primer, 5-ACA GGC ATT GTG ACC AGC AA-3; CYP3A37:
probe, 5-TTG GCC CAG GAA TGC CCA GCT-3; forward
primer, 5-GTC CCA AAG AAA GGC AAT GGT 3; reverse
primer, 5-GGC CAT TTG GGT TGT TCA AG-3; ALAS: probe,
5-TTC CGC CAT AAC GAC GTC AAC CAT CTT- 3; forward
primer, 5-GCA GGG TGC CAA AAC ACA T-3; reverse
primer, 5-TCG ATG GAT CAG ACT TCT TCA ACA-3; glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH): probe,
5-TGG CGT GCC CAT TGA TCA CAA GTT T-3; forward
primer, 5-GGT CAC GCT CCT GGA AGA TAG T-3; reverse
primer, 5-GGG CAC TGT CAA GGC TGA GA-3. CYP2H1,
CYP3A37, ALAS, and GAPDH transcript levels were mea-
sured in separate tubes, and GAPDH was used for normal-
ization of the CYP2H1, the CYP3A37, and the ALAS values.
Western Blot Analysis
Chicken embryo livers were frozen in liquid nitrogen and
crushed in a mortar. The tissue was resuspended in 10 mM
HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1
mM dithiothreitol, and 0.5 mM phenylmethylsulfonyl fluoride
(lysis buffer) and sonicated three times for 10 sec on ice. The
extract was centrifuged at 4 C for 20 min at 14,000 rpm.
Chick embryo hepatocytes were cultured and prepared as
previously described (53, 54). Primary hepatocytes and LMH
cells were washed twice with PBS, resuspended in lysis
buffer, sonicated, and centrifuged as described above. The
protein concentration of the supernatant was determined
using the ESL protein assay (Roche Molecular Biochemicals).
Equal amounts of protein were separated on 10% Tricine-
SDS-PAGE. The proteins were blotted onto a NYTRAN 13 N
membrane (Schleicher & Schuell, Inc., Dassel, Germany) us-
ing a Multiphor II Nova Blot (Pharmacia LKB, Du¨bendorf,
Switzerland) and 39 mM glycine, 48 mM Tris, 0.0375% SDS,
and 20% methanol for semidry transfer of the proteins at 0.8
mA/cm2 for 1 h. Proteins were visualized according to the
enhanced chemiluminescence protocol (Amersham Pharma-
cia Biotech, Zu¨rich, Switzerland) using an anti-CYP2H1 anti-
body. This polyclonal rabbit antibody was generously
provided by Dr. P. Sinclair (VA Hospital, White River
Junction, VT).
Northern Blot Analysis
Total RNA (10 g) was subjected to electrophoresis on a 1%
agarose/formamide gel. RNA was transferred to a NYTRAN
13 N membrane (Schleicher & Schuell, Inc.) overnight in 10
SSC (1.5 M NaCl, 150 mM sodium citrate) and was cross-
linked to the membrane by UV exposure for 12 sec. Prehy-
bridization was carried out in 50% formamide, 5 SSC, 5
Denhardt’s solution, 1% SDS, and 10% (wt/vol) dextran sul-
fate. Hybridization probes were generated by PCR amplifica-
tion using the primers mentioned above and labeled with
[-32P]dATP using the Random Primed DNA Labeling Kit
(Roche Molecular Biochemicals). The probes were boiled for
5 min in 500 l of 10 mg/ml salmon sperm DNA and chilled
on ice. Hybridization was carried out for 16–20 h at 42 C.
Washes were performed in 2 SSC/0.1% SDS at room tem-
perature for 30 min and in 2 SSC/0.1% SDS at 65 C for 20
min. Membranes were exposed to x-ray film using intensify-
ing screens or to PhosphorImager screens for 12–48 h.
EMSAs
Chicken CXR and chicken RXR were synthesized in vitro
using the TNT T7 Quick Coupled Transcription/Translation
System (Promega Corp., Catalys AG, Wallisellen, Switzer-
land) according to the manufacturer’s instructions. Chicken
RXR was chosen for these experiments because RXR is
the only chicken RXR ortholog known so far. Probes were
labeled with Klenow enzyme in the presence of radiolabeled
32P--ATP, and the probe was purified over a Biospin 30
Chromatography Column (Bio-Rad Laboratories, Inc., Glatt-
brugg, Switzerland). A volume of labeled oligonucleotide cor-
responding to 100,000 cpm was used for each reaction in 10
mM Tris (pH 8.0), 40 mM KCl, 0.05% NP-40, 6% glycerol, 1
mM dithiothreitol, 0.4 g/l BSA, 0.2 g poly(dI-dC)*poly(dI-
dC), and 2.5 l of each of the in vitro synthesized proteins as
described previously (22). To test for supershifts, 0.5 l of
monoclonal antimouse-RXR rabbit antibody (kindly provided
by Dr. P. Chambon, IGBMC, Universite´ Louis Pasteur, Illkirch,
France) was added to the reaction mix. This antibody has
been positively tested for cross-reaction with the chicken
RXR in Western blots (data not shown). The mix was incu-
bated for 20 min at room temperature and subsequently
electrophoresed on a 6% polyacrylamide gel in 0.25 Tris-
Borate-EDTA buffer followed by autoradiography at 70 C.
Transcriptional Activation Assays
To perform transactivation assays, CV-1 cells were kept in
DMEM/F12 medium without phenol red, supplemented with
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10% charcoal-stripped FBS, and plated in six-well dishes at
a density of 625,000 cells per well. A total of 2.5 g DNA per
well, including 150 ng of receptor expression vector, 400 ng
of CAT reporter gene plasmid, 800 ng pSV--galactosidase
expression vector (Promega Corp.) and carrier plasmid were
transfected and cells were exposed to drugs. Cell extracts
were prepared and assayed for CAT using a CAT-ELISA kit
(Roche Molecular Biochemicals). -Galactosidase activities
were determined. CAT concentrations were then normalized
against -galactosidase values to compensate for varying
transfection efficiencies as described previously (22).
Acknowledgments
Received December 20, 2000. Accepted June 1, 2001.
Address requests for reprints to: Urs A. Meyer, Division of
Pharmacology/Neurobiology, Biozentrum of the University of
Basel, Klingelbergstrasse 70, CH-4056 Basel, Switzerland.
E-mail: Urs-A.Meyer@unibas.ch.
This work was supported by the Swiss National Science
Foundation.
* Present address: Friedrich Miescher Institute, Maulbeer-
strasse 66, CH-4058 Basel, Switzerland.
† ProteinGenesys Ltd., Rheinstrasse 28, CH-4302 Augst,
Switzerland.
REFERENCES
1. Nelson DR, Koymans L, Kamataki T, et al. 1996 P450
superfamily: update on new sequences, gene mapping,
accession numbers and nomenclature. Pharmacogenet-
ics 6:1–42
2. Waxman DJ, Azaroff L 1992 Phenobarbital induction of
cytochrome P-450 gene expression. Biochem J 281:
577–592
3. Beato M, Herrlich P, Schu¨tz G 1995 Steroid hormone
receptors: many actors in search of a plot. Cell 83:
851–857
4. Dogra SC, Whitelaw ML, May BK 1998 Transcriptional
activation of cytochrome P450 genes by different classes
of chemical inducers. Clin Exp Pharmacol Physiol 25:1–9
5. Waxman DJ 1999 P450 Gene induction by structurally
diverse xenochemicals: central role of nuclear receptors
CAR, PXR and PPAR. Arch Biochem Biophys 369:11–23
6. Kliewer SA, Lehmann JM, Willson TM 1999 Orphan nu-
clear receptors: shifting endocrinology into reverse. Sci-
ence 284:757–760
7. Savas U, Griffin KJ, Johnson EF 1999 Molecular mech-
anisms of cytochrome P-450 induction by xenobiotics:
an expanded role for nuclear hormone receptors. Mol
Pharmacol 56:851–857
8. Honkakoski P, Negishi M 2000 Regulation of cytochrome
P450 (CYP) genes by nuclear receptors. Biochem J 347:
321–337
9. Kemper B 1998 Regulation of cytochrome P450 gene
transcription by phenobarbital. Prog Nucleic Acid Res
Mol Biol 61:23–64
10. Frueh FW, Zanger UM, Meyer UA 1997 Extent and char-
acter of phenobarbital-mediated changes in gene ex-
pression in liver. Mol Pharmacol 51:363–369
11. Lehmann JM, McKee DD, Watson MA, Willson TM,
Moore JT, Kliewer SA 1998 The human orphan nuclear
receptor PXR is activated by compounds that regulate
CYP3A4 gene expression and cause drug interaction.
J Clin Invest 102:1016–1023
12. Jones SA, Moore LB, Shenk JL, et al. 2000 The pregnane
X receptor: a promiscuous xenobiotic receptor that has
diverged during evolution. Mol Endocrinol 14:27–39
13. Trottier E, Belzil A, Stoltz C, Anderson A 1995 Localiza-
tion of a phenobarbital-responsive element (PBRE) in the
5-flanking region of the rat CYP2B2 gene. Gene 158:
263–268
14. Honkakoski P, Negishi M 1997 Characterization of a
phenobarbital-responsive enhancer module in mouse
P450 Cyp2b10 gene. J Biol Chem 272:14943–14949
15. Honkakoski P, Moore R, Washburn KA, Negishi M 1998
Activation by diverse xenochemicals of the 51-base pair
phenobarbital-responsive enhancer module in the
CYP2b10 Gene. Mol Pharmacol 53:597–601
16. Stoltz C, Vachon MH, Trottier E, Dubois S, Paquet Y,
Anderson A 1998 The CYP2B2 phenobarbital response
unit contains an accessory factor element and a putative
glucocorticoid response element essential for conferring
maximal phenobarbital responsiveness. J Biol Chem
273:8528–8536
17. Dogra SC, Davidson BP, May BK 1999 Analysis of a
phenobarbital-responsive enhancer sequence located in
the 5 flanking region of the chicken CYP2H1 gene: iden-
tification and characterization of functional protein-bind-
ing sites. Mol Pharmacol 55:14–22
18. Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P, Negishi
M 1999 The repressed nuclear receptor CAR responds to
phenobarbital in activating the human CYP2B6 gene.
J Biol Chem 274:6043–6046
19. Handschin C, Meyer UA 2000 A conserved nuclear re-
ceptor consensus sequence (DR-4) mediates transcrip-
tional activation of the chicken CYP2H1 gene by pheno-
barbital in a hepatoma cell line. J Biol Chem 275:
13362–13369
20. Kliewer SA, Moore JT, Wade L, et al. 1998 An orphan
nuclear receptor activated by pregnanes defines a novel
steroid signaling pathway. Cell 92:73–82
21. Honkakoski P, Zelko I, Sueyoshi T, Negishi M 1998 The
nuclear orphan receptor CAR-retinoid X receptor het-
erodimer activates the phenobarbital-responsive en-
hancer module of the CYP2B gene. Mol Cell Biol 18:
5652–5658
22. Handschin C, Podvinec M, Meyer UA 2000 CXR, a
chicken xenobiotic-sensing orphan nuclear receptor, is
related to both mammalian pregnane X receptor (PXR)
and constitutive androstane receptor (CAR). Proc Natl
Acad Sci USA 97:10769–10774
23. Honkakoski P, Moore R, Gynther J, Negishi M 1996
Characterization of phenobarbital-inducible mouse
Cyp2b10 gene transcription in primary hepatocytes.
J Biol Chem 271:9746–9753
24. Kolluri S, Elbirt KK, Bonkovsky HL 1999 Heme biosyn-
thesis in a chicken hepatoma cell line (LMH): comparison
with primary chick embryo liver cells (CELC). Biochim
Biophys Acta 1472:658–667
25. Kawaguchi T, Nomura K, Hirayama Y, Kitagawa T 1987
establishment and characterization of a chicken hepato-
cellular carcinoma cell line, LMH. Cancer Res 47:
4460–4464
26. Gabis KK, Gildemeister OS, Pepe JA, Lambrecht RW,
Bonkovsky HL 1996 Induction of heme oxygenase-1 in
LMH cells. Comparison of LMH cells to primary cultures
of chick embryo liver cells. Biochim Biophys Acta 1290:
113–120
27. Mattschoss LA, Hobbs AA, Steggles AW, May BK, Elliott
WH 1986 isolation and characterization of genomic
clones for two chicken phenobarbital-inducible cyto-
chrome P-450 genes. J Biol Chem 261:9438–9443
28. Ourlin JC, Baader M, Fraser D, Halpert JR, Meyer UA
2000 Cloning and functional expression of a first induc-
ible avian cytochrome P450 of the CYP3A subfamily
(CYP3A37). Arch Biochem Biophys 373:375–384
29. May BK, Dogra SC, Sadlon TJ, Bhasker CR, Cox TC,
Bottomley SS 1995 Molecular regulation of heme bio-
synthesis in higher vertebrates. Prog Nucleic Acid Res
Mol Biol 51:1–51
1584 Mol Endocrinol, September 2001, 15(9):1571–1585 Handschin et al. • Conservation of Orphan Nuclear Receptors
30. Jover R, Hoffmann K, Meyer UA 1996 Induction of 5-
aminolevulinate synthase by drugs is independent of in-
creased apocytochrome P450 synthesis. Biochem Bio-
phys Res Commun 226:152–157
31. Zelko I, Negishi M 2000 Phenobarbital-elicited activation
of nuclear receptor CAR in induction of cytochrome P450
genes. Biochem Biophys Res Commun 277:1–6
32. Morgan ET, Sewer MB, Iber H, et al. 1998 Physiological
and pathophysiological regulation of cytochrome P450.
Drug Metab Dispos 26:1232–1240
33. Weigel NL, Zhang Y 1998 Ligand-independent activation
of steroid hormone receptors. J Mol Med 76:469–79
34. Shao D, Lazar MA 1999 Modulating nuclear receptor
function: may the phos be with you. J Clin Invest 103:
1617–1618
35. Kawamoto T, Sueyoshi T, Zelko I, Moore R, Washburn K,
Negishi M 1999 Phenobarbital-responsive nuclear trans-
location of the receptor CAR in induction of the CYP2B
gene. Mol Cell Biol 19:6318–6322
36. Sidhu JS, Omiecinski CJ 1996 Forskolin-mediated in-
duction of CYP3A1 mRNA expression in primary rat
hepatocytes is independent of elevated intracellular cy-
clic AMP. J Pharmacol Exp Ther 276:238–245
37. Sidhu JS, Omiecinski CJ 1997 An okadaic acid-sensitive
pathway involved in the phenobarbital-mediated induc-
tion of CYP2B gene expression in primary rat hepatocyte
cultures. J Pharmacol Exp Ther 282:1122–1129
38. Nirodi CS, Sultana S, Ram N, Prabhu L, Padmanaban G
1996 Involvement of synthesis and phosphorylation of
nuclear protein factors that bind to the positive cis-acting
element in the transcriptional activation of the
CYP2B1/B2 gene by phenobarbitone in vivo. Arch Bio-
chem Biophys 331:79–86
39. Honkakoski P, Negishi M 1998 Protein serine/threonine
phosphatase inhibitors suppress phenobarbital-induced
Cyp2b10 gene transcription in mouse primary hepato-
cytes. Biochem J 330:889–895
40. Beck NB, Omiecinski CJ 1999 Lack of modulation by
phenobarbital of cyclic AMP levels or protein kinase A
activity in rat primary hepatocytes. Biochem Pharmacol
58:1109–1114
41. Hahn CN, Hansen AJ, May BK 1991 Transcriptional reg-
ulation of the chicken CYP2H1 gene. J Biol Chem 266:
17031–17039
42. Paquet Y, Trottier E, Beaudet MJ, Anderson A 2000
Mutational analysis of the CYP2B2 phenobarbital re-
sponse unit and inhibitory effect of the constitutive an-
drostane receptor on phenobarbital responsiveness.
J Biol Chem 275:38427–38436
43. Baes M, Gulick T, Choi HS, Martinoli MG, Simha D,
Moore DD 1994 A new orphan member of the nuclear
hormone receptor superfamily that interacts with a sub-
set of retinoic acid response elements. Mol Cell Biol
14:1544–1552
44. Choi HS, Chung M, Tzameli I, et al. 1997 Differential
transactivation by two isoforms of the orphan nuclear
hormone receptor CAR. J Biol Chem 272:23565–23571
45. Tzameli I, Pissios P, Schuetz EG, Moore DD 2000 The
xenobiotic compound 1,4-bis[2-(3, 5-dichloropyridyl-
oxy)]benzene is an agonist ligand for the nuclear receptor
CAR. Mol Cell Biol 20:2951–2958
46. Moore LB, Parks DJ, Jones SA, et al. 2000 Orphan
nuclear receptors constitutive androstane receptor and
pregnane X receptor share xenobiotic and steroid li-
gands. J Biol Chem 275:15122–15127
47. Hunter T 1995 Protein kinases and phosphatases: the yin
and yang of protein phosphorylation and signaling. Cell
80:225–236
48. Sidhu JS, Omiecinski CJ 1995 cAMP-associated inhibi-
tion of phenobarbital-inducible cytochrome P450 gene
expression in primary rat hepatocyte cultures. J Biol
Chem 270:12762–12773
49. Xie W, Barwick JL, Downes M, et al. 2000 Humanized
xenobiotic response in mice expressing nuclear receptor
SXR. Nature 406:435–439
50. Russell DW 1999 Nuclear orphan receptors control cho-
lesterol catabolism. Cell 97:539–542
51. Chawla A, Saez E, Evans RM 2000 “Don’t know much
bile-ology.” Cell 103:1–4
52. Howard WR, Pospisil JA, Njolito E, Noonan DJ 2000
Catabolites of cholesterol synthesis pathways and fors-
kolin as activators of the farnesoid X-activated nuclear
receptor. Toxicol Appl Pharmacol 163:195–202
53. Althaus FR, Sinclair JF, Sinclair P, Meyer UA 1979 Drug-
mediated induction of cytochrome(s) P-450 and drug
metabolism in cultured hepatocytes maintained in chem-
ically defined medium. J Biol Chem 254:2148–2153
54. Giger U, Meyer UA 1981 Induction of -aminolevulinate
synthase and cytochrome P-450 hemoproteins in hepa-
tocyte culture. Effect of glucose and hormones. J Biol
Chem 256:11182–11190
Handschin et al. • Conservation of Orphan Nuclear Receptors Mol Endocrinol, September 2001, 15(9):1571–1585 1585
